ASCO 2019 Archives -

Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this

Deep Dive: Oncology and ASCO 2019

https://pharmaphorum.com/oncology/deep-dive-oncology-asco-2019/

ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 round-up

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up

ASCO 2019 round-up

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/

ASCO 2019 and the future of oncology/ Oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – phase I data generates hope for the future

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future.

ASCO 2019 – phase I data generates hope for the future

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/

ASCO 2019 Live coverage/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 day five

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

Exclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago. •

ASCO 2019 day five

https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-five/

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Enfortumab comes out fighting in bladder cancer

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC)

ASCO 2019 – Enfortumab comes out fighting in bladder cancer

https://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/

Kantar video image ASCO 2019 clinical practices

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase

ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results

https://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/

ASCO 2019 and the future of oncology/ News/ News/ Oncology/ Top stories

Sanofi trumpets Darzalex rival isatuximab in refractory myeloma

Phil Taylor ASCO 2019, cancer, myeloma, Oncology 0 Comment

Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38

Sanofi trumpets Darzalex rival isatuximab in refractory myeloma

https://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/

Trending

ASCO 2019

Login